Case number 1:22-cv-00032
Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 29, 2022 | 35 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (Attachments: # 1 Consent Judgment)(nms) (Entered: 11/29/2022) (Consent Judgment) (5) |
| Nov 29, 2022 | 35 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (Attachments: # 1 Consent Judgment)(nms) (Entered: 11/29/2022) (Main Document) (1) |
| Nov 28, 2022 | 34 | REDACTED VERSION of 32 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/29/2022 (nms). (Entered: 11/28/2022) (5) |
| Nov 21, 2022 | 33 | [SEALED] CONSENT JUDGMENT and Order of Injunction between Plaintiff and Defendant "Alkem. Signed by Judge Richard G. Andrews on 11/21/2022.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01330-RGA, 1:22-cv-00032-RGA(nms) (Entered: 11/21/2022) (0) |
| Nov 18, 2022 | 32 | [SEALED] PROPOSED Consent Judgment and Order of Injunction as to Alkem, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/18/2022) (0) |
| Aug 29, 2022 | 31 | SCHEDULING ORDER: Joinder of Parties due by 1/5/2023. Amended Pleadings due by 1/5/2023. Fact Discovery completed by 6/16/2023. Joint Claim Construction Brief due by 3/31/2023. A Markman Hearing is set for 4/14/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 2/2/2024, at 9:00 AM in Courtroom 6A. A 7 day Bench Trial is set to start 2/12/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 8/29/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 08/29/2022) (21) |
| Aug 26, 2022 | 30 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/28/2022 (nms). (Entered: 08/26/2022) (21) |
| Aug 17, 2022 | 29 | Official Transcript of Rule 16 Conference held on 8/3/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/7/2022. Redacted Transcript Deadline set for 9/19/2022. Release of Transcript Restriction set for 11/15/2022. (Triozzi, Heather) (Entered: 08/17/2022) (29) |
| Aug 3, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Scheduling Conference held on 8/3/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: E. Ormerod, A. Poff, R. Weinblatt, C. Hitch, D. Gattuso, B. Palapura, J. Seaman. Plaintiff is directed to submit the revised order. (Court Reporter Heather Triozzi.) Associated Cases: 1:22-cv-00032-RGA et al.(lak) |
| Jul 27, 2022 | 28 | Redacted Document (10) Docket Text: REDACTED VERSION of [25] Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/28/2022 (nms). |
| Jul 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) |
| Jun 15, 2022 | 24 | Proposed Order (21) Docket Text: PROPOSED Scheduling Order (with disputed provisions), by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/15/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 10, 2022 | 23 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION and Proposed Order Extending Time to submit Proposed Scheduling Order to June 15, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 9, 2022 | 22 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to June 10, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Jun 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to June 10, 2022. Signed by Judge Richard G. Andrews on 6/9/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to June 8, 2022. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 1, 2022 | 20 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME the parties' deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 8, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to and including June 1, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 25, 2022 | 19 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 1, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 18, 2022 | 18 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| May 11, 2022 | 17 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 18, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 18, 2022. Signed by Judge Richard G. Andrews on 5/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/5/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 4, 2022 | 16 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 25, 2022 | 15 | Answer to Counterclaim (8) Docket Text: ANSWER to [13] Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:21-cv-01330-LPS et al. (ntl) |
| Apr 4, 2022 | 14 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Apr 4, 2022 | 13 | Answer to Complaint (27) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Apr 4, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jared L. Stringham for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 4, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Nicholas N. Kallas and Christina Schwarz for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 1, 2022 | 12 | Status Report (9) Docket Text: Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [9] STIPULATION and Order dismissing S&B Pharma, Inc. without prejudice and amending the case caption to reflect the same filed by Alkem Laboratories Ltd. -- Party S&B Pharma, Inc. terminated. Signed by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (9 in 1:22-cv-00186-LPS, 9 in 1:22-cv-00083-LPS, 10 in 1:22-cv-00032-LPS) MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 3/29/22. Associated Cases: 1:22-cv-00032-LPS, 1:22-cv-00083-LPS, 1:22-cv-00186-LPS (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [8] STIPULATION TO EXTEND TIME for Defendant Alkem Laboratories Ltd. to answer the Complaint to April 4, 2022 filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 23, 2022 | 10 | Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, J (4) |
| Mar 23, 2022 | 10 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Jared L. Stringham)(Joyce, Alexandra) |
| Mar 21, 2022 | 9 | Stipulation (4) Docket Text: STIPULATION dismissing S&B Pharma, Inc. without prejudice and amending the case caption to reflect the same by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Mar 21, 2022 | 8 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Defendant Alkem Laboratories Ltd. to answer the Complaint to April 4, 2022 - filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Mar 2, 2022 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. S&B Pharma, Inc. served on 3/1/2022, answer due 3/22/2022. (Joyce, Alexandra) |
| Mar 2, 2022 | 6 | Exhibit A-B (7) |
| Mar 2, 2022 | 6 | Main Document (2) Docket Text: DECLARATION of Service of Alkem Laboratories Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits A-B)(Joyce, Alexandra) Modified on 4/8/2022 (nms). |
| Jan 12, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (nms) |
| Jan 7, 2022 | 1 | Complaint* (1) |
| Jan 7, 2022 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (myr) |
| Jan 7, 2022 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (myr) |
| Jan 7, 2022 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than November 23, 2021. Date of Expiration of Patent: May 9, 2036.Thirty Month Stay Deadline: 7/7/2023. (myr) |
| Jan 7, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (myr) |
| Jan 7, 2022 | 1 | Civil Cover Sheet (2) |
| Jan 7, 2022 | 1 | Exhibit A (16) |
| Jan 7, 2022 | 1 | Main Document (12) Docket Text: COMPLAINT filed against Alkem Laboratories Ltd., S&B Pharma, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3776867.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(myr) |
| Jan 7, 2022 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (myr) |
